恒瑞医药(01276.HK)：子公司“HRS-7535 片”获药物临床试验批准

Core Viewpoint - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical, has received approval from the National Medical Products Administration for the clinical trial of HRS-7535 tablets, which will be used to treat chronic kidney disease [1]. Group 1: Drug Information - Drug Name: HRS-7535 tablets [1] - Dosage Form: Tablet [1] - Application Matter: Clinical trial [1] - Acceptance Numbers: CXHL2501214, CXHL2501215, CXHL2501216 [1] Group 2: Approval Details - Approval Conclusion: HRS-7535 tablets meet the requirements for drug registration and are allowed to proceed with Phase III clinical trials [1] - Application Indication: Intended for the treatment of chronic kidney disease [1] - Acceptance Date: November 5, 2025 [1]